JPMorgan Chase & Co. Raises Hikma Pharmaceuticals (LON:HIK) Price Target to GBX 1,800

Hikma Pharmaceuticals (LON:HIK) had its target price raised by JPMorgan Chase & Co. from GBX 1,700 ($22.21) to GBX 1,800 ($23.52) in a research report released on Tuesday, Stock Target Advisor reports. They currently have a neutral rating on the stock.

Other research analysts also recently issued research reports about the company. Barclays reissued an equal weight rating on shares of Hikma Pharmaceuticals in a report on Monday, November 18th. Peel Hunt restated a hold rating on shares of Hikma Pharmaceuticals in a report on Wednesday, November 27th. Citigroup restated a buy rating on shares of Hikma Pharmaceuticals in a report on Thursday, November 7th. Jefferies Financial Group reaffirmed a buy rating on shares of Hikma Pharmaceuticals in a research report on Friday, November 15th. Finally, Morgan Stanley reiterated an equal weight rating on shares of Hikma Pharmaceuticals in a research note on Wednesday, November 13th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and two have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of Hold and an average target price of GBX 1,798.33 ($23.50).

LON:HIK opened at GBX 1,896 ($24.77) on Tuesday. The firm has a 50-day moving average of GBX 1,944.80 and a two-hundred day moving average of GBX 1,884.40. The company has a debt-to-equity ratio of 37.69, a current ratio of 1.28 and a quick ratio of 0.78. The stock has a market cap of $4.58 billion and a P/E ratio of 12.74. Hikma Pharmaceuticals has a 1-year low of GBX 1,491.50 ($19.49) and a 1-year high of GBX 2,212 ($28.90).

About Hikma Pharmaceuticals

Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment manufactures, markets, and sells generic injectable products for therapeutic categories, including oncology and anti-viral products to hospitals.

Featured Story: What does relative strength index mean?

Analyst Recommendations for Hikma Pharmaceuticals (LON:HIK)

Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit